Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification.
Izzo NJ, Yuede CM, LaBarbera KM, Limegrover CS, Rehak C, Yurko R, Waybright L, Look G, Rishton G, Safferstein H, Hamby ME, Williams C, Sadlek K, Edwards HM, Davis CS, Grundman M, Schneider LS, DeKosky ST, Chelsky D, Pike I, Henstridge C, Blennow K, Zetterberg H, LeVine H 3rd, Spires-Jones TL, Cirrito JR, Catalano SM.
Izzo NJ, et al. Among authors: chelsky d.
Alzheimers Dement. 2021 Aug;17(8):1365-1382. doi: 10.1002/alz.12302. Epub 2021 Feb 8.
Alzheimers Dement. 2021.
PMID: 33559354
Free PMC article.
Clinical Trial.